pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 28·1 min read
save

Rocket's PRV goes for $180M; Oruka targets $500M offering

Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...

Apr 28, 2026·read at Endpoints ↗

April 28, 2026 10:54 AM EDT News Briefing Rock­et's PRV goes for $180M; Oru­ka tar­gets $500M of­fer­ing ENDPOINTS Rock­et sells PRV for $180M: The New Jer­sey gene ther­a­py mak­er sold the rare pe­di­atric dis­ease pri­or­i­ty re­view vouch­er to an … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
74 words · retrieved Apr 28
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.2
drugs
Undisclosed
topics
Rare Disease2Gene Therapy (AAV)

related stories

  • 14h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Aug 18LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugBioSpace
  • Aug 14After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?Fierce Biotech
  • Dec 23Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount dropFierce Biotech
  • Dec 22Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120MFierce Biotech